Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > June 8, 2020
Daily News
June 8, 2020
- Chugai Files FoundationOne as Lynparza CDx for mCRPC
June 8, 2020
- Meiji Pharma Jettisons Nail Ringworm Med ME1111
June 8, 2020
- Opdivo Gets Taiwan Nod for Second-Line Esophageal Cancer
June 8, 2020
- MHLW Grants Orphan Status to 8 APIs
June 8, 2020
- Japan Pharma Trade Group Nudges Govt to Postpone Off-Year Re-Pricing
June 8, 2020
- Ono Kicks Off Japan Clinical Study for Pancreatitis Med Foipan for COVID-19
June 8, 2020
- Minister Mentions First Half 2021 Goal for Coronavirus Vaccination Start
June 8, 2020
- Patient Advocacy Group Urges MLHW to Increase Funding for Pancreatic Cancer Research
June 8, 2020
- ASEAN + 3 Ministers Vow to Work towards Smooth Drug Distribution amid COVID-19
June 8, 2020
- Rakuten Medical, MD Anderson Pair Up on Cancer Photoimmunotherapy
June 8, 2020
- Eylea Pre-Filled Syringe Now Available in Japan: Bayer, Santen
June 8, 2020
- Nipro Launches Stemirac Manufacturing Facility in Tokyo
June 8, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…